ORCID Profile
0000-0002-7730-7305
Current Organisation
Auckland University of Technology
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 03-2016
Publisher: Royal Society of Chemistry (RSC)
Date: 2021
DOI: 10.1039/D1RA02961D
Abstract: The photophysical properties of different structural isomers of naphthalene bridged disilanes are distinct. The presence of the Si–Si bond is key to excimer formation in non-polar solvents.
Publisher: Elsevier BV
Date: 10-2014
Publisher: Elsevier BV
Date: 2019
DOI: 10.1016/J.EJMECH.2018.11.020
Abstract: Fluorescent scriptaid analogues with excellent HDAC6 selectivity (HDAC1/6 > 500) and potency (HDAC6 IC
Publisher: Elsevier BV
Date: 09-2016
DOI: 10.1016/J.CELREP.2016.08.005
Abstract: Drugs that recapitulate aspects of the exercise adaptive response have the potential to provide better treatment for diseases associated with physical inactivity. We previously observed reduced skeletal muscle class IIa HDAC (histone deacetylase) transcriptional repressive activity during exercise. Here, we find that exercise-like adaptations are induced by skeletal muscle expression of class IIa HDAC mutants that cannot form a corepressor complex. Adaptations include increased metabolic gene expression, mitochondrial capacity, and lipid oxidation. An existing HDAC inhibitor, Scriptaid, had similar phenotypic effects through disruption of the class IIa HDAC corepressor complex. Acute Scriptaid administration to mice increased the expression of metabolic genes, which required an intact class IIa HDAC corepressor complex. Chronic Scriptaid administration increased exercise capacity, whole-body energy expenditure and lipid oxidation, and reduced fasting blood lipids and glucose. Therefore, compounds that disrupt class IIa HDAC function could be used to enhance metabolic health in chronic diseases driven by physical inactivity.
Publisher: Elsevier BV
Date: 04-2012
Publisher: Royal Society of Chemistry (RSC)
Date: 2015
DOI: 10.1039/C5CC02059J
Abstract: Fluorescent 4MS , has comparable HDAC and anticancer activity to scriptaid and allows visualisation of rapid cellular uptake and cytoplasmic localisation.
Publisher: American Chemical Society (ACS)
Date: 30-01-2014
DOI: 10.1021/JM401945K
Abstract: An improved synthesis and structural reassignment of the class IIa selective histone deacetylase (HDAC) inhibitor MC1568 are described.
Start Date: 2021
End Date: 2024
Funder: Marsden Fund
View Funded Activity